231 related articles for article (PubMed ID: 22371181)
21. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
Chiron D; Bellanger C; Papin A; Tessoulin B; Dousset C; Maiga S; Moreau A; Esbelin J; Trichet V; Chen-Kiang S; Moreau P; Touzeau C; Le Gouill S; Amiot M; Pellat-Deceunynck C
Blood; 2016 Dec; 128(24):2808-2818. PubMed ID: 27697772
[TBL] [Abstract][Full Text] [Related]
22. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
23. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
24. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis.
Lwin T; Crespo LA; Wu A; Dessureault S; Shu HB; Moscinski LC; Sotomayor E; Dalton WS; Tao J
Leukemia; 2009 Jan; 23(1):170-7. PubMed ID: 18843286
[TBL] [Abstract][Full Text] [Related]
25. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
[TBL] [Abstract][Full Text] [Related]
26. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
Mraz M; Zent CS; Church AK; Jelinek DF; Wu X; Pospisilova S; Ansell SM; Novak AJ; Kay NE; Witzig TE; Nowakowski GS
Br J Haematol; 2011 Oct; 155(1):53-64. PubMed ID: 21749361
[TBL] [Abstract][Full Text] [Related]
28. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis.
Zak Z; Gelebart P; Lai R
Leukemia; 2010 Aug; 24(8):1476-86. PubMed ID: 20520642
[TBL] [Abstract][Full Text] [Related]
29. CXCL13 production by an established lymph node stromal cell line via lymphotoxin-beta receptor engagement involves the cooperation of multiple signaling pathways.
Suto H; Katakai T; Sugai M; Kinashi T; Shimizu A
Int Immunol; 2009 Apr; 21(4):467-76. PubMed ID: 19251935
[TBL] [Abstract][Full Text] [Related]
30. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
Kurtova AV; Tamayo AT; Ford RJ; Burger JA
Blood; 2009 May; 113(19):4604-13. PubMed ID: 19228923
[TBL] [Abstract][Full Text] [Related]
31. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
32. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
33. Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells.
Cippitelli M; Stabile H; Kosta A; Petillo S; Lucantonio L; Gismondi A; Santoni A; Fionda C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768145
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
[TBL] [Abstract][Full Text] [Related]
36. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
[TBL] [Abstract][Full Text] [Related]
37. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Shishodia S; Amin HM; Lai R; Aggarwal BB
Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
[TBL] [Abstract][Full Text] [Related]
38. Neutrophils trigger a NF-κB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas.
Grégoire M; Guilloton F; Pangault C; Mourcin F; Sok P; Latour M; Amé-Thomas P; Flecher E; Fest T; Tarte K
Oncotarget; 2015 Jun; 6(18):16471-87. PubMed ID: 26158216
[TBL] [Abstract][Full Text] [Related]
39. The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples.
Camara-Clayette V; Lecluse Y; Schrader C; Klapper W; Vainchenker W; Hermine O; Ribrag V
Eur J Cancer; 2014 Jan; 50(1):159-69. PubMed ID: 24135685
[TBL] [Abstract][Full Text] [Related]
40. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
